These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 17673601

  • 1. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.
    Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC.
    Blood; 2007 Nov 15; 110(10):3561-3. PubMed ID: 17673601
    [Abstract] [Full Text] [Related]

  • 2. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
    Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V.
    Ann Hematol; 2010 Jun 15; 89(6):579-84. PubMed ID: 20012043
    [Abstract] [Full Text] [Related]

  • 3. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
    Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M.
    Blood; 2011 Oct 20; 118(16):4346-52. PubMed ID: 21828140
    [Abstract] [Full Text] [Related]

  • 4. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.
    Bone Marrow Transplant; 2001 Oct 20; 28(7):637-42. PubMed ID: 11704785
    [Abstract] [Full Text] [Related]

  • 5. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
    Batalini F, Econimo L, Quillen K, Sloan JM, Sarosiek S, Brauneis D, Havasi A, Stern L, Dember LM, Sanchorawala V.
    Biol Blood Marrow Transplant; 2018 Jan 20; 24(1):127-132. PubMed ID: 28865972
    [Abstract] [Full Text] [Related]

  • 6. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
    Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC.
    Bone Marrow Transplant; 2007 Sep 20; 40(6):557-62. PubMed ID: 17589534
    [Abstract] [Full Text] [Related]

  • 7. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.
    Landau H, Smith M, Landry C, Chou JF, Devlin SM, Hassoun H, Bello C, Giralt S, Comenzo RL.
    Leukemia; 2017 Jan 20; 31(1):136-142. PubMed ID: 27560108
    [Abstract] [Full Text] [Related]

  • 8. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
    Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V.
    Transpl Infect Dis; 2013 Apr 20; 15(2):187-94. PubMed ID: 23279695
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.
    Girnius S, Seldin DC, Meier-Ewert HK, Sloan JM, Quillen K, Ruberg FL, Berk JL, Doros G, Sanchorawala V.
    Bone Marrow Transplant; 2014 Mar 20; 49(3):434-9. PubMed ID: 24317129
    [Abstract] [Full Text] [Related]

  • 10. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.
    Br J Haematol; 2004 Dec 20; 127(5):543-51. PubMed ID: 15566357
    [Abstract] [Full Text] [Related]

  • 11. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
    Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA.
    Blood; 2012 Feb 02; 119(5):1117-22. PubMed ID: 22147893
    [Abstract] [Full Text] [Related]

  • 12. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
    Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Kumar SK, Leung N, Lust J, Rajkumar SV, Russell SJ, Suman VJ, Le-Rademacher JG, Hogan WJ.
    Cancer; 2016 Jul 15; 122(14):2197-205. PubMed ID: 27142462
    [Abstract] [Full Text] [Related]

  • 13. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis.
    Quillen K, Seldin DC, Finn KT, Sanchorawala V.
    Bone Marrow Transplant; 2011 Jul 15; 46(7):976-80. PubMed ID: 20956955
    [Abstract] [Full Text] [Related]

  • 14. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ, Klippel ZK, Stevenson PA, Hyun TS, Tuazon S, Becker PS, Green DJ, Holmberg LA, Coffey DG, Gopal AK, Libby EN.
    Amyloid; 2016 Dec 15; 23(4):254-259. PubMed ID: 27879147
    [Abstract] [Full Text] [Related]

  • 15. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC.
    Biol Blood Marrow Transplant; 2015 Aug 15; 21(8):1445-51. PubMed ID: 25858810
    [Abstract] [Full Text] [Related]

  • 16. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, Rahman H, Sloan JM, Sarosiek S, Sanchorawala V.
    Biol Blood Marrow Transplant; 2018 Sep 15; 24(9):1823-1827. PubMed ID: 29933072
    [Abstract] [Full Text] [Related]

  • 17. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
    Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG.
    Ann Intern Med; 2004 Jan 20; 140(2):85-93. PubMed ID: 14734330
    [Abstract] [Full Text] [Related]

  • 18. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.
    Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V.
    Blood; 2006 Dec 01; 108(12):3945-7. PubMed ID: 16926284
    [Abstract] [Full Text] [Related]

  • 19. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
    Hayashi T, Ikeda H, Igarashi T, Maruyama Y, Aoki Y, Nojima M, Ishida T, Shinomura Y.
    Int J Hematol; 2014 Dec 01; 100(6):554-8. PubMed ID: 25281404
    [Abstract] [Full Text] [Related]

  • 20. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
    Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M.
    Bone Marrow Transplant; 2004 Feb 01; 33(4):381-8. PubMed ID: 14676787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.